000299000 001__ 299000
000299000 005__ 20250318095036.0
000299000 0247_ $$2doi$$a10.1016/j.canlet.2025.217581
000299000 0247_ $$2pmid$$apmid:39983894
000299000 0247_ $$2ISSN$$a0304-3835
000299000 0247_ $$2ISSN$$a1872-7980
000299000 037__ $$aDKFZ-2025-00410
000299000 041__ $$aEnglish
000299000 082__ $$a570
000299000 1001_ $$aAbooali, Maryam$$b0
000299000 245__ $$aIntracellular and extracellular activities of V-domain Ig-containing suppressor of T cell activation (VISTA) modulated by immunosuppressive factors of tumour microenvironment.
000299000 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000299000 3367_ $$2DRIVER$$aarticle
000299000 3367_ $$2DataCite$$aOutput Types/Journal article
000299000 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1742287798_3582
000299000 3367_ $$2BibTeX$$aARTICLE
000299000 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000299000 3367_ $$00$$2EndNote$$aJournal Article
000299000 500__ $$a2025 Apr 28;616:217581
000299000 520__ $$aV-domain Ig-containing suppressor of T cell activation (VISTA) is a unique immune checkpoint protein, which was reported to display both receptor and ligand activities. However, the mechanisms of regulation of VISTA activity and functions by factors of tumour microenvironment (TME) remain unclear and understanding these processes is required in order to develop successful personalised cancer immunotherapeutic strategies and approaches. Here we report for the very first time that VISTA interacts with another immune checkpoint protein galectin-9 inside the cell most likely facilitating its interaction with TGF-β-activated kinase 1 (TAK1). This process is required for protection of lysosomes, which is crucial for many cell types and tissues. We found that VISTA expression can be differentially controlled by crucial factors present in TME, such as transforming growth factor beta type 1 (TGF-β) and hypoxia as well as other factors activating hypoxic signalling. We confirmed that involvement of these important pathways modulated by TME differentially influences VISTA expression in different cell types. These networks include: TGF-β-Smad3 pathway, TAK1 (TGF-β-activated kinase 1) or apoptosis signal-regulating kinase 1 (ASK1)-induced activation of activating transcription factor 2 (ATF-2) and hypoxic signalling pathway. Based on this work we determined the five critical functions of VISTA and the role of TME factors in controlling (modulating or downregulating) VISTA expression.
000299000 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000299000 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000299000 7001_ $$0P:(DE-He78)0b6e32bf4b6d335c6b11d5edaef8bfd3$$aSchlichtner, Stephanie$$b1$$udkfz
000299000 7001_ $$aLei, Xi$$b2
000299000 7001_ $$aAliu, Nijas$$b3
000299000 7001_ $$aRuggiero, Sabrina$$b4
000299000 7001_ $$0P:(DE-HGF)0$$aLoges, Sonia$$b5
000299000 7001_ $$0P:(DE-He78)62a3cc13c7db450aa0e711ce99b43d7b$$aZiegler, Martin$$b6$$udkfz
000299000 7001_ $$0P:(DE-He78)470d596989d1c5c31fdaa5a2b638e5ae$$aHertel, Franziska$$b7$$udkfz
000299000 7001_ $$aVolckmar, Anna-Lena$$b8
000299000 7001_ $$aStenzinger, Albrecht$$b9
000299000 7001_ $$aChristopoulos, Petros$$b10
000299000 7001_ $$aThomas, Michael$$b11
000299000 7001_ $$aKlenova, Elena$$b12
000299000 7001_ $$aMeyer, N Helge$$b13
000299000 7001_ $$aBoussios, Stergios$$b14
000299000 7001_ $$aHeaton, Nigel$$b15
000299000 7001_ $$aZen, Yoh$$b16
000299000 7001_ $$aZamalloa, Ane$$b17
000299000 7001_ $$aChokshi, Shilpa$$b18
000299000 7001_ $$aUrbani, Luca$$b19
000299000 7001_ $$aRichard, Sophie$$b20
000299000 7001_ $$aKirubendran, Kavitha$$b21
000299000 7001_ $$aHussain, Rohanah$$b22
000299000 7001_ $$aSiligardi, Giuliano$$b23
000299000 7001_ $$aCholewa, Dietmar$$b24
000299000 7001_ $$aBerger, Steffen M$$b25
000299000 7001_ $$aYasinska, Inna M$$b26
000299000 7001_ $$aFasler-Kan, Elizaveta$$b27
000299000 7001_ $$aSumbayev, Vadim V$$b28
000299000 773__ $$0PERI:(DE-600)2004212-7$$a10.1016/j.canlet.2025.217581$$gp. 217581 -$$p217581$$tCancer letters$$v616$$x0304-3835$$y2025
000299000 909CO $$ooai:inrepo02.dkfz.de:299000$$pVDB
000299000 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0b6e32bf4b6d335c6b11d5edaef8bfd3$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000299000 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000299000 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)62a3cc13c7db450aa0e711ce99b43d7b$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000299000 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)470d596989d1c5c31fdaa5a2b638e5ae$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000299000 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000299000 9141_ $$y2025
000299000 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-16$$wger
000299000 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER LETT : 2022$$d2024-12-16
000299000 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000299000 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000299000 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-16
000299000 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-16
000299000 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000299000 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-16
000299000 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000299000 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-16
000299000 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-16
000299000 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000299000 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000299000 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER LETT : 2022$$d2024-12-16
000299000 9201_ $$0I:(DE-He78)A420-20160331$$kA420$$lPersonalisierte Medizinische Onkologie$$x0
000299000 980__ $$ajournal
000299000 980__ $$aVDB
000299000 980__ $$aI:(DE-He78)A420-20160331
000299000 980__ $$aUNRESTRICTED